Clinical

Dataset Information

0

Phase II Multicenter, Randomised, Open-Label Study to Evaluate the Efficacy and Safety of Tislelizumab in combination with Cetuximab and Irinotecan versus Investigator’s Choice in patients with previously treated RAS wild-type advanced colorectal cancer

ABSTRACT: Interventions: Experimental Arm:Tislelizumab and cetuximab and irinotecan;Control Arm:Standard Treatment Primary outcome(s): progression-free survival Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 40399 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.
| S-EPMC9982342 | biostudies-literature
Unknown Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
| S-EPMC12139608 | biostudies-literature
Unknown Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
| S-EPMC6886121 | biostudies-literature
Unknown Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
| S-EPMC8461541 | biostudies-literature
Unknown Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.
| S-EPMC7780053 | biostudies-literature
Unknown An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.
| S-EPMC8325221 | biostudies-literature
Unknown Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
| S-EPMC8207822 | biostudies-literature
Unknown Continuous positive airway pressure and mandibular advancement splints: the CHOICE multicentre, open-label randomised clinical trial.
| S-EPMC11965959 | biostudies-literature
Unknown Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
| S-EPMC9939146 | biostudies-literature
Unknown Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors.
| S-EPMC11230881 | biostudies-literature